• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Arcellx Inc.

    4/28/26 4:19:01 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACLX alert in real time by email
    S-8 POS 1 tm2612746d1_s8pos.htm S-8 POS

    As filed with the Securities and Exchange Commission on April 28, 2026 

    Registration No. 333-262571

    Registration No. 333-269105

    Registration No. 333-276346

    Registration No. 333-284136

    Registration No. 333-292559

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-262571

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-269105

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-276346

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-284136

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-292559

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Arcellx, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   47-2855917
    (State or other jurisdiction of
    incorporation or organization)
     

    (IRS employer

    identification number)

     

    800 Bridge Parkway

    Redwood City, CA 94065

    (Address of Principal Executive Offices)

     

    2022 Equity Incentive Plan

    2017 Equity Incentive Plan

    2022 Employee Stock Purchase Plan

    (Full title of the Plans)

     

    Andrew D. Dickinson

    President and Treasurer

    Arcellx, Inc.

    333 Lakeside Drive

    Foster City, CA 94404

    (Name and address of agent for service)

     

    (240) 327-0630

    (Telephone number, including area code, of agent for service)

     

     

    Copy to:

     

    Emily Oldshue

    Nicholas Roper

    Ropes & Gray LLP

    Prudential Tower, 800 Boylston Street

    Boston, Massachusetts 02199

    (617) 951-7000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.   ¨

     

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    These Post-Effective Amendments (these “Post-Effective Amendments”) are being filed by Arcellx, Inc. (the “Registrant”) to deregister all shares of the Registrant’s common stock, par value $0.001 per share (“Shares”), that remain unissued under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) previously filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”):

     

      ·   Registration Statement No. 333-262571 pertaining to the registration of (i) 1,512,859 Shares issuable under the Registrant’s 2022 Equity Incentive Plan (the “2022 Plan”), (ii) 2,784,016 Shares issuable pursuant to options outstanding under the Registrant’s 2022 Plan, (iii) 312,500 Shares issuable under the Registrant’s 2022 Employee Stock Purchase Plan (the “2022 ESPP”), (iv) 5,316,437 Shares issuable pursuant to options outstanding under the Registrant’s 2017 Equity Incentive Plan (the “2017 Plan”) and (v) 952,804 Shares issuable pursuant to restricted stock units outstanding under the Registrant’s 2017 Plan, which was filed with the SEC on February 7, 2022.
           
      ·   Registration Statement No. 333-269105 pertaining to the registration of (i) 2,205,299 Shares issuable under the Registrant’s 2022 Plan and (ii) 312,500 Shares issuable under the Registrant’s 2022 ESPP, as amended and restated, which was filed with the SEC on January 3, 2023.
           
      ·   Registration Statement No. 333-276346 pertaining to the registration of (i) 2,613,888 Shares issuable under the Registrant’s 2022 Plan and (ii) 312,500 Shares issuable under the Registrant’s 2022 ESPP, as amended and restated, which was filed with the SEC on January 2, 2024.
           
      ·   Registration Statement No. 333-284136 pertaining to the registration of (i) 2,714,041 Shares issuable under the Registrant’s 2022 Plan and (ii) 312,500 Shares issuable under the Registrant’s 2022 ESPP, as amended and restated, which was filed with the SEC on January 6, 2025.
           
      ·   Registration Statement No. 333-292559 pertaining to the registration of (i) 2,895,867 Shares issuable under the Registrant’s 2022 Plan and (ii) 312,500 Shares issuable under the Registrant’s 2022 ESPP, as amended and restated, which was filed with the SEC on January 2, 2026.

     

    On April 28, 2026, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of February 22, 2026, by and among the Registrant, Gilead Sciences, Inc. (“Parent”) and Ravens Sub, Inc. (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and becoming a wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in each Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under such Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of each Registration Statement and removes from registration all of the securities that remain unsold under each Registration Statement as of the date hereof, if any. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Registrant pursuant to the Registration Statements.

     

    The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 23, 2026.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on April 28, 2026.

     

      ARCELLX, INC.
         
      By: /s/ Andrew D. Dickinson
        Name: Andrew D. Dickinson
        Title:  President and Treasurer

     

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

     

     

    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX

    DatePrice TargetRatingAnalyst
    2/12/2026$82.00Buy → Neutral
    Rothschild & Co Redburn
    1/7/2026$100.00Buy
    UBS
    12/22/2025$100.00Overweight
    Wells Fargo
    11/18/2025Peer Perform
    Wolfe Research
    10/16/2025$129.00Buy
    Stifel
    6/17/2025$110.00Buy
    Citigroup
    10/8/2024$109.00Buy
    Redburn Atlantic
    9/3/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Carroll Jill to satisfy tax liability

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/28/26 6:22:20 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Behbahani Ali closing all direct ownership in the company (SEC Form 4) to satisfy tax liability

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/28/26 4:34:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Ware Olivia C

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/28/26 4:31:18 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arcellx downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral and set a new price target of $82.00

    2/12/26 7:20:24 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Arcellx with a new price target

    Wells Fargo initiated coverage of Arcellx with a rating of Overweight and set a new price target of $100.00

    12/22/25 8:37:37 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACLX
    SEC Filings

    View All

    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim

    4/28/26 8:45:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger

    DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and accelerating immunotherapy revenues, today's tape reflects capital flowing toward platforms with validation. Kraig Biocraft Laboratories Featured on National Geographic Cover Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) could see elevated interest after the company's recombinant spider silk technology landed on the cover of the March 2026 issue of National Geographic. KBLB) recombinant spider silk technology is featured on the cover of the March 2026 issue of National Geog

    2/23/26 9:36:14 AM ET
    $ACLX
    $GETY
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate

    Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

    – Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma – – Provides Gilead with Full Control of Anito-cel, Accelerating Development and Commercialization while Eliminating Profit-Share, Milestones, and Royalties – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (NASDAQ:ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing.

    2/23/26 6:01:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 15-12G filed by Arcellx Inc.

    15-12G - Arcellx, Inc. (0001786205) (Filer)

    5/8/26 4:12:59 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Arcellx Inc.

    SCHEDULE 13D/A - Arcellx, Inc. (0001786205) (Subject)

    4/30/26 5:38:06 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Arcellx Inc.

    S-8 POS - Arcellx, Inc. (0001786205) (Filer)

    4/28/26 4:24:11 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Leadership Updates

    Live Leadership Updates

    View All

    Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

    -- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market

    3/20/25 4:00:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel

    REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters. 

    6/21/22 4:05:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx Appoints Michelle Gilson as Chief Financial Officer

    FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

    5/23/22 4:05:00 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Financials

    Live finance-specific insights

    View All

    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim

    4/28/26 8:45:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

    -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --   -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --  -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx

    12/9/22 8:15:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

    SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

    11/14/24 4:35:36 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcellx Inc.

    SC 13G/A - Arcellx, Inc. (0001786205) (Subject)

    11/14/24 4:31:50 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care